Jump to navigation Jump to search
Chloropyramine Wiki Str.png
Clinical data
ATC code
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass289.803

WikiDoc Resources for Chloropyramine


Most recent articles on Chloropyramine

Most cited articles on Chloropyramine

Review articles on Chloropyramine

Articles on Chloropyramine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Chloropyramine

Images of Chloropyramine

Photos of Chloropyramine

Podcasts & MP3s on Chloropyramine

Videos on Chloropyramine

Evidence Based Medicine

Cochrane Collaboration on Chloropyramine

Bandolier on Chloropyramine

TRIP on Chloropyramine

Clinical Trials

Ongoing Trials on Chloropyramine at Clinical

Trial results on Chloropyramine

Clinical Trials on Chloropyramine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Chloropyramine

NICE Guidance on Chloropyramine


FDA on Chloropyramine

CDC on Chloropyramine


Books on Chloropyramine


Chloropyramine in the news

Be alerted to news on Chloropyramine

News trends on Chloropyramine


Blogs on Chloropyramine


Definitions of Chloropyramine

Patient Resources / Community

Patient resources on Chloropyramine

Discussion groups on Chloropyramine

Patient Handouts on Chloropyramine

Directions to Hospitals Treating Chloropyramine

Risk calculators and risk factors for Chloropyramine

Healthcare Provider Resources

Symptoms of Chloropyramine

Causes & Risk Factors for Chloropyramine

Diagnostic studies for Chloropyramine

Treatment of Chloropyramine

Continuing Medical Education (CME)

CME Programs on Chloropyramine


Chloropyramine en Espanol

Chloropyramine en Francais


Chloropyramine in the Marketplace

Patents on Chloropyramine

Experimental / Informatics

List of terms related to Chloropyramine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Chloropyramine is a classical ("old" or first generation) antihistamine drug approved in some Eastern European countries for the treatment of allergic conjuctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.

Chloropyramine is known as a competitive reversible H1-receptor antagonist (also known as an H1 inverse agonist), meaning that it exerts its pharmacological action by competing with histamine for the H1 subtype histamine receptor. By blocking the effects of histamine, the drug inhibits the vasodilation, increased vascular permeability, and tissue edema associated with histamine release in the tissue. The H1-antagonistic properties of chloropyramine can be used by researchers for the purposes of blocking the effects of histamine on cells and tissues. In addition, chloropyramine has some anticholinergic properties.

Chloropyramine's anticholinergic properties and the fact that it can pass through the blood-brain barrier are linked to its clinical side effects: drowsiness, weakness, vertigo, fatigue, dryness in the mouth, constipation, and rarely - visual disturbances and increase of intraocular pressure.

Clinical dosage and administration

In cases of severe allergic reactions, chloropyramine can be injected intramuscularly or intravenously. Oral administration: In adults, 25 mg can be taken 3 to 4 times daily (up to 150 mg); in children over 5 years-old, 25 mg can be taken 2 to 3 times daily. For external application, the skin or the conjuctiva of the eye can be treated up to several times a day by applying a thin layer of cream or ointment containing 1% chloropyramine hydrochloride.


Contraindications for parenteral or oral administration include adenoma of the prostate, acute peptic ulcer, pyloric and duodenal stenosis, glaucoma, pregnancy, breast-feeding.

Special warnings and precautions

Chloropyramine should not be used internally with alcohol, sedative drugs and hypnotics because of the potentiation of the effects. It should be used with caution in patients suffering from hyperthyroidism, cardiovascular diseases, and bronchial asthma. In children, it can induce agitation, and in many adult patients dizziness may be observed. Because of the pronounced sedative effect the preparation should be prescribed cautiously in drivers and people working with machines.

Drug interactions

Chloropyramine should not be used internally with MAO inhibitors. Because of its anticholinergic activity, concurrent administration with cholinomimetics is not advisable. General anesthetics, analgesic agents and psycholeptics potentiate the sedative effect of chloropyramine. Template:Antipruritics